DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies
TORCH-Plus
TranslatiOnal Registry for CardiomyopatHies (TORCH) - Plus as Part of the German Centre for Cardiovascular Research (DZHK)
1 other identifier
observational
2,040
1 country
1
Brief Summary
The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP). As a multi-center German cardiomyopathy registry, TORCH has been prospectively admitting patients since December 2014. 2,300 patients were recruited as planned. Taken together, patient data showed that the prevalence of these diseases is much higher in men than in women, atrial fibrillation is common in all forms of CMPs as well as rare forms of disease indicate a higher risk and higher morbidity. This DZHK TORCH register is now to be expanded with a second phase (DZHK TORCH-Plus). The second phase DZHK TORCH-Plus consists of 4 main modules: 1. "Clinical phenotyping, follow-up \& biosampling" 2. "Genomics", 3. "Inflammation" and 4. "Biomarker". The central aims are 1) to significantly increase the number of probands (n = 4340) in order to better address the different types of CMPs, especially patients with rare CMP forms such as LVNC and ARVC or with probably molecularly explainable cardiomyopathies (familial DCM), 2) to prolong the longitudinal with a further follow-up to achieve sufficient events and thereby derive clinical recommendations for risk assessment, 3) to increase the number of probands with state-of-the-art phenotyping, 4) to pinpoint the effect of myocardial inflammation, fibrosis, gender and to determine or predict genotypes based for outcome, 5) to validate novel biomarkers developed in other DZHK studies, and 6) to foster active cooperation with international CMP registries and partners from industry.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 7, 2020
CompletedFirst Posted
Study publicly available on registry
February 11, 2020
CompletedStudy Start
First participant enrolled
August 18, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2027
November 30, 2023
November 1, 2023
7.3 years
February 7, 2020
November 29, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
all-cause mortality
4 years
Eligibility Criteria
Primary care clinic
You may qualify if:
- Non-ischemic structural cardiomyopathies
- Age ≥ 18 or ≤ 80 years
- The patient is able to understand the declaration of consent and to sign it dated
- At least one of the following diagnoses depending on the specific TORCH-
- Dilated Cardiomyopathy (DCM)
- family / genetic
- inflammatory / persistent myocarditis
- left sided systolic dysfunction (EF ≤ 45%)
- Left ventricular hypertrophy
- sarcomere hypertrophic cardiomoypathia (HCM, HOCM)
- amyloid (AL: light chains, TTR: transthyretin, wild type)
- Left ventricular non-compaction cardiomyopathy (LVNC)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC / D)
You may not qualify if:
- Age: \<18 years or\> 80 years
- Patient has other (cardiac) previous illnesses:
- uncontrollable arterial hypertension
- primary pulmonary arterial hypertension
- radiation therapy in the chest area
- addiction (drug or alcohol abuse)
- life expectancy \<1 year due to non-cardiological pre-existing conditions
- significant heart valve disease
- ischemic diseases and severe congenital heart diseases (including VSD, Fallot tetralogy, Ebstein anomaly)
- chemotoxic cardiomyopathy
- condition after myocarditis
- combination of several traditional risk factors (e.g. hypertension and diabetes mellitus)
- advanced chronic non-cardiac disease (e.g. chronic hepatitis or HIV)
- Tachymyopathy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital Heidelberglead
- University Medicine Greifswaldcollaborator
- Charite University, Berlin, Germanycollaborator
- German Heart Centercollaborator
- University of Mannheimcollaborator
- University Hospital Schleswig-Holsteincollaborator
- Medical University of Hannovercollaborator
- Goethe Universitycollaborator
- Universitätsklinikum Hamburg-Eppendorfcollaborator
- University Medical Center Mainzcollaborator
- University Medical Center Goettingencollaborator
- Deutsches Herzzentrum Muenchencollaborator
- Technical University of Munichcollaborator
- University Hospital Munichcollaborator
- Kerckhoff Klinikcollaborator
Study Sites (1)
University Hospital Heidelberg - Clinic of Cardiology, Angiology and Pneumology
Heidelberg, Baden-Wurttemberg, 69120, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Target Duration
- 4 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Deputy Director - Clinic of Cardiology, Angiology and Pneumology
Study Record Dates
First Submitted
February 7, 2020
First Posted
February 11, 2020
Study Start
August 18, 2020
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Last Updated
November 30, 2023
Record last verified: 2023-11